natgillin/translations-raw huggingface dataset:
the thyroid gland does not work properly (too little hormone is produced) (hypothyroidism)
motnje v delovanju ščitnice (proizvede se premalo hormona) (hipotiroidizem)
the thyroid gland does not work properly (too little hormone is produced) (hypothyroidism),
motnje delovanja ščitnice (proizvaja se premalo hormona) (hipotiroidizem)
the thyroid gland does not work properly(thyroid disorders), too much hormone is produced (hyperthyroidism), inflammation of the pancreas (pancreatitis), see section 2 “Warnings and precautions”, blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uraemic syndrome).
nepravilno delovanje ščitnice (bolezni ščitnice) proizvaja se preveč hormona (hipertiroidizem) vnetje trebušne slinavke (pankreatitis), glejte poglavje 2 Opozorila in previdnostni ukrepi krvni strdki v majhnih krvnih žilah, ki lahko vplivajo na delovanje ledvic (trombotična trombocitopenična purpura ali hemolitično-uremični sindrom).
The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual.
Za vse vrste insulina velja, da se lahko časovni potek delovanja insulina med posamezniki, pa tudi pri vsakem posamezniku v različnih časovnih obdobjih, znatno razlikuje.
The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual
Časovni potek delovanja insulina in insulinskih analogov, kakršen je insulin glargin, se lahko zelo razlikuje tako med posamezniki kot pri eni in isti osebi.
The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual.
Časovni potek delovanja insulina in insulinskih analogov, kakršen je insulin glargin, se lahko zelo razlikuje tako med posamezniki kot pri eni in isti osebi.
The time difference between countries may mean that you have to have your injections and meals at different times from when you are at home.
Zaradi časovne razlike med državami boste morda morali na potovanjih jesti obroke in si injicirati insulin ob drugih urah dneva, kakor če bi bili doma.
The time from start of administration of sugammadex or neostigmine to recovery of the T4/T1 ratio to 0.9 was:
Čas od začetka dajanja sugamadeksa oziroma neostigmina bolniku do povrnitve razmerja T4/T1 na vrednost 0,9 je znašal:
The time of intake must be noted.
Točen čas zaužitja je treba zapisati.
The time taken to fall asleep was reduced in adults taking Zerene 10 mg, and the effects were maintained for up to four weeks.
Pri odraslih, ki so vzeli 10 mg zdravila Zerene, se je skrajšal čas, potreben, da so zaspali, učinki pa so trajali do štiri tedne.
The time to 10% of total INS exposure was reached earlier by approximately 5–6 min with insulin glulisine.
Z insulinom lispro je bila 10 % skupna INS izpostavljenost dosežena približno 5-6 minut hitreje.
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109 /l was 13 days (range 9-29 days) in allogenic patients (OMC-BUS 4), and 10 days (range 8-19 days) in autologous patients (OMC-BUS 3).
Čas za doseg absolutnega števila nevtrofilcev, večjega od 0,5 x 109/l , je bil pri alogenskih bolnikih (OMC-BUS-4) 13 dni (v razponu 9-29 dni), pri avtolognih bolnikih (OMC-BUS-3) pa 10 dni (v razponu 8-19 dni).
The time to Absolute Neutrophil Count (ANC) greater than 0.5x109/l was 21 days (range 12-47 days) in allogenic patients, and 11 days (range 10-15 days) in autologous patients.
Čas, potreben, da je skupno število nevtrofilcev (Absolute Neutrophil Count – ANC) preseglo 0,5 x 109/l, je bil pri alogenskih bolnikih 21 dni (interval 12–47 dni), pri avtolognih bolnikih pa 11 dni (interval 10–15 dni).
The time to first SBM in the LIR subgroup after taking the first dose was shorter for the 25 mg dose as compared to placebo in Kodiac 4 (p<0.001) and Kodiac 5 (p=0.002).
Čas do prvega spontanega iztrebljanja je bil v podskupini LIR po uporabi prvega odmerka v skupini s 25 mg krajši kot s placebom tako v Kodiac 4 (p < 0,001) kot v Kodiac 5 (p = 0,002).
The time to first skeletal-related event at the 25th percentile in the ZYTIGA group was twice that of the control group at 9.9 months versus 4.9 months.
Vrednost 25. percentile časa do prvega z okostjem povezanega dogodka je bila v skupini z zdravilom ZYTIGA dvakrat višja kot v kontrolni skupini, in sicer 9,9 meseca v primerjavi s 4,9 meseca.
The time to pain improvement (i.e.,  2 point decrease from baseline in BPI-SF worst pain score) was similar for denosumab and zoledronic acid in each study and the integrated analyses.
Čas do zmanjšanja bolečine (tj. zmanjšanje za  2 točki v primerjavi z izhodiščem po BPI-SF skali najslabše ocene bolečin) je bil z denosumabom in zoledronsko kislino podoben v vsaki študiji zase in v skupnih analizah.
The time to pain progression at the 25th percentile was 7.4 months in the ZYTIGA group, versus 4.7 months in the placebo group.
Vrednost 25. percentile časa do napredovanja bolečine je bila v skupini z zdravilom ZYTIGA 7,4 mesecev v primerjavi s 4,7 meseci v skupini s placebom.
The time to peak insulin concentration (Tmax) is generally half of that for subcutaneously administered fast-acting human insulin.
Čas do najvišje koncentracije insulina (Tmax) je na splošno za polovico krajši od tistega pri subkutano injiciranem hitrodelujočem topnem humanem insulinu.
The time to peak plasma concentrations of A771726 is very variable; peak plasma levels can occur between between 1 hour and 24 hours after single administration.
Čas do najvišje plazemske koncentracije A771726 je zelo različen; najvišja koncentracija v plazmi se lahko pojavi med 1 in 24 urami po enkratnem odmerku.
The time to peak, terminal half-life and mean residence time were not affected by ketoconazole (see section 4.4).
Ketokonazol ni vplival na čas do največje koncentracije, končno razpolovno dobo in srednji čas zadrževanja v telesu (glejte poglavje 4.4).
The time to recovery from succinylcholine-induced neuromuscular blockade (1 mg/kg) was compared with sugammadex (16 mg/kg, 3 minutes later) – induced recovery from rocuronium-induced neuromuscular blockade (1.2 mg/kg).
Čas do prekinitve živčnomišične blokade, sprožene s sukcinilholinom (1 mg/kg), so primerjali s časom, ki je potreben, da sugamadeks (v odmerku 16 mg/kg, ki so ga dali čez 3 minute) odpravi živčnomišično blokado, sproženo z rokuronijem (v odmerku 1,2 mg/kg).
the time window if this resulted in no virologic data on treatment during the specified window. e Includes subjects who discontinued for reasons other than an adverse event, death, or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up. f Plus background regimen of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg fixed-dose combination
ki niso neželeni učinki, smrt ali pomanjkanje oz. izguba učinkovitosti, in so imele v času prekinitve virološko vrednost ≥ 50 kopij/ml. d Vključuje bolnike, ki so prenehali sodelovati zaradi neželenih učinkov ali smrti, kadar koli od 1. dne do konca časovnega okna, če zaradi tega v določenem oknu ni bilo viroloških podatkov o zdravljenju. e Vključuje osebe, ki so sodelovanje prekinile zaradi razlogov, ki niso neželeni učinki, smrt ali pomanjkanje ali izguba učinkovitosti, npr. umik soglasja, izgubljeni za spremljanje. f Plus osnovi režim s fiksno kombinacijo emtricitabina 200 mg in dizoproksiltenofovirata fumarata 300 mg
The time you eat meals and use your insulin.
Glede časa, ko uživate obroke in uporabljate insulin.
The timing of leukapheresis: 1 or 2 leukaphereses on days 5 and 6 which is often sufficient.
Časovni razpored levkafereze: eno do dve levkaferezi 5 in 6. dan, kar pogosto zadošča.
The timing of leukapheresis: 1 or 2 leukaphereses on days 5 and 6 which is often sufficient.
Časovni razpored levkafereze: eno do dve levkaferezi in 6. dan, kar pogosto zadošča.
The timing of leukapheresis: one or two leukaphereses on days 5 and 6 which is often sufficient.
Časovni razpored levkafereze: eno do dve levkaferezi in 6. dan, kar pogosto zadošča.
The timing of ovulation cannot be predicted and therefore ellaOne should be taken as soon as possible after unprotected intercourse.
Časa ovulacije ni mogoče predvideti, zato je treba vzeti zdravilo ellaOne čim prej po nezaščitenem spolnem odnosu.
The timing of the injection is adjusted according to the dates of mating and farrowing (giving birth).
Časovno obdobje injiciranja cepiva se prilagodi glede na datume pripustitve in prasitve (kotenja).
The tiny air bubbles in the insulin reservoir that do not move with tapping will not interfere with the injection and dosage.
Drobni mehurčki zraka, ki so v insulinskem rezervoarju in se pri trkanju ne premikajo, ne motijo odmerjanja in injiciranja.
The tiny air bubbles in the insulin reservoir that do not move with tapping will not interfere with the injection and dose.
Drobni mehurčki zraka, ki so v insulinskem rezervoarju in se pri trkanju ne premikajo, ne motijo odmerjanja in injiciranja.
The tiny particles of medicine in the capsule are picked up by the airflow and carried down your airway into your lungs.
S pretokom zraka skozi dihalne poti se drobni delci zdravila prenesejo iz kapsule v pljuča.
The tip cap from the Removab pre-filled syringe is removed with the tip pointing up.
Odstranite pokrov konice z injekcijske brizge, napolnjene z zdravilom Removab, tako da gleda konica brizge navzgor.
The tip of the tube should not come into contact with the wound or any other surface.
Vrh tube ne sme priti v stik z rano ali katerokoli drugo površino.
The titration pack also contains a titration guide providing information on the titration process and allowing you to record the number of tablets you take every day.
Titracijsko pakiranje vsebuje tudi titracijsko navodilo z informacijami o postopku titracije, v katerega lahko beležite število tablet, ki jih vsak dan vzamete.
The tmax for tylvalosin is about 2.2 hours; the terminal half-life for the elimination is approximately 2.2 hours.
Tmax tilvalozina je okrog 2,2 uri; terminalni razpolovni čas odstranjevanja iz telesa je približno 2,2 uri.
The Tmax of monomethyl fumarate is 2 to 2.5 hours.
Tmax monometil fumarata je 2 do 2,5 ure.
The tmax of ramipril and ramiprilat were delayed by approximately 2.5 hours.
AUC in Cmax aktivnega presnovka (ramiprilata) se nista spremenili. tmax ramiprila in ramiprilata sta se podaljšala za približno 2,5 ure.
The tmax was delayed by approximately 1 hour compared to that under fasted conditions
Tmax je bil podaljšan za približno 1 uro v primerjavi s tistim na tešče.
The TOBI Podhaler Phase III clinical development programme consisted of two studies and 612 treated patients with a clinical diagnosis of CF, confirmed by quantitative pilocarpine iontophoresis sweat chloride test or well-characterised disease causing mutations in each cystic fibrosis transmembrane regulator (CFTR) gene, or abnormal nasal transepithelial potential difference characteristic of CF.
Faza III kliničnega razvoja zdravila TOBI Podhaler je obsegala dve študiji in 612 zdravljenih bolnikov s klinično diagnozo cistične fibroze, potrjeno s testom vsebnosti kloridov v znoju s kvantitativno pilokarpinsko iontoforezo ali z dobro opredeljeno boleznijo, ki povzroča mutacije v obeh CFTR genih (genih za regulator transmembranskega prenosa pri cistični fibrozi – cystic fibrosis transmembrane regulator - CFTR) ali s patološko vrednostjo razlike električnega potenciala nosne sluznice, ki je značilna za cistično fibrozo.
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z zdravilom
The tolerance and dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing
Prenašanje in odmerek zdravila je treba oceniti v 3 mesecih od začetka
The tolerance and dose should be assessed within three months after starting treatment, and
Prenašanje in odmerek zdravila je treba oceniti v treh mesecih od začetka zdravljenja, od takrat naprej pa je treba koristi zdravljenja z
The Tolero nebuliser handset must be cleaned and disinfected as described in the instructions for use of the device.
Nebulator Tolero je treba očistiti in razkužiti, kot je opisano v navodilih za uporabo tega pripomočka.
the top of the thighs
zgornji del stegen
the top of your thighs, the abdomen (see grey areas in picture 3) avoiding the skin directly surrounding the navel.
zgornji del stegen in trebuh (glejte sive predele na sliki 3), pri čemer se izognite koži neposredno okoli popka.
the top of your thighs, the abdomen (see grey areas in picture 4) avoiding the skin directly surrounding the navel.
zgornji del stegen in trebuh (glejte sive predele na sliki 4), pri čemer se izognite koži neposredno okoli popka.
the top of your thighs, the abdomen, except for the area around the navel (see grey areas in picture 5).
zgornji del stegna, trebuh, razen območja okrog popka (glejte siva območja na sliki 5).
the top of your thighs, the abdomen, except for the area around the navel (see grey areas in picture 6).
zgornji del stegna, trebuh, razen območja okrog popka (glejte siva območja na sliki 6).
the top of your thighs; and the abdomen, except for the area around the navel (see picture 3).
zgornji del stegen; in trebuh, razen predela okrog popka (glejte sliko 3).
the top of your thighs; and the abdomen, except for the area around the navel.
zgornji del stegen in trebuh (razen predela okrog popka).
the top of your thighs; and the abdomen, except for the area around the navel.
zgornji del stegen; in trebuh, razen predela okrog popka.
The topical anaesthetic or oral analgesic should be used in accordance with the medicinal product’s instructions for use.
Topikalni anestetik ali peroralni analgetik je treba uporabljati v skladu z navodilom za njegovo uporabo.
The topical corticosteroid can be maintained in case of persistent ocular inflammation.
Topikalno dajanje kortikosteroida se lahko pri trdovratnem vnetju očesa nadaljuje.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0 %.
Topotekan-O-glukuronid in N- desmetil topotekan-O-glukuronid sta v urinu v manj kot 2,0 %.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0 %.
Topotekan-O-glukuronid in N-desmetil topotekan-O-glukuronid sta navzoča v seču v manj kot 2,0 %.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0 %.
Topotekan-O-glukuronid in N-desmetil topotekan-O-glukuronid sta v urinu v manj kot 2,0 %.
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were less than 2.0%.
Topotekan-O-glukuronid in N-desmetil topotekan-O-glukuronid sta v urinu v manj kot 2,0 %.
The total amount of lamivudine ingested by a breastfed infant is very low and is therefore likely to result in exposures exerting a sub-optimal antiviral effect.
Celotna količina lamivudina, ki ga zaužije dojenček, je zelo majhna in zato verjetno povzroči izpostavljenosti, katere protivirusni učinek je suboptimalen.
The total amount of sulphur hexafluoride administered in a clinical dose is extremely small, (in a 2 ml dose the microbubbles contain 16 µl of gas).
Celokupna količina žveplovega heksafluorida v kliničnem odmerku je izredno majhna (2 ml odmerek vsebuje 16 µl plina v obliki mikromehurčkov).
The total and maximum-glucose-lowering effects of Ryzodeg increase linearly with increasing doses.
Celotni učinek in največje znižanje koncentracije glukoze se pri zdravilu Ryzodeg povečujeta linearno s povečevanjem odmerka.
The total body and renal clearance are 157 - 176 and 3 - 3.5 ml/min, respectively.
Celokupni telesni in ledvični očistek je 157- 176 oziroma 3-3,5 ml/min.
The total body clearance of selexipag is 17.9 L/h.
Skupni očistek seleksipaga iz telesa je 17,9 l/h.
The total body clearance of sildenafil is 41 L/h with a resultant terminal phase half-life of 3-5 h.
Celotni telesni očistek sildenafila je 41 l/h in razpolovni čas terminalne faze je od 3 do 5 ur.
The total body clearance of sildenafil is 41 l/h with a resultant terminal phase half-life of 3-5 h.
Celotni telesni očistek sildenafila je 41 l/h, razpolovni čas terminalne faze pa je od 3 do 5 ur.
The total body clearance of sildenafil is 41 L/h with a resultant terminal phase half-life of 3-5 h.
Celotni telesni očistek sildenafila je 41 L/uro, razpolovni čas terminalne faze pa je od 3 do 5 ur.
The total body clearance of the medicinal product following an i.v. dose is relatively high at between
Skupni očistek zdravila iz telesa po intravenskem odmerku je razmeroma visok in znaša od
The total body clearance of vardenafil is 56 l/h with a resultant terminal half-life of approximately
Celoten očistek vardenafila iz telesa znaša 56 l/h.
The total clearance (mean ±SD) is approximately 58±5 l/h after an intravenous administration with renal clearance accounting for about 22% of this.
Skupni očistek (povprečje ± SD) po intravenski uporabi je približno
The total clearance of AsIII over the single-dose range of 7-32 mg (administered as 0.15 mg/kg) is 49 L/h and the renal clearance is 9 L/h.
Skupni očistek AsIII v razponu enkratnega odmerka 7-32 mg (aplicirano kot 0,15 mg/kg) je 49 L/h in ledvični očistek je 9 L/h.
The total clearance of thiotepa ranged from 11.4 to 23.2 l/h/m2.
Celotni očistek tiotepe je bil med 11,4 do 23,3 l/h/m2.
The total clearance of thiotepa ranged from 11.4 to 23.2 l/h/m2.
Celotni očistek tiotepe je bil od 11,4 do 23,3 l/h/m2.
The total clearance of tocilizumab was concentration-dependent and is the sum of the linear and non-linear clearance.
Celotni očistek tocilizumaba je odvisen od koncentracije in je vsota linearnega in nelinearnega očistka.
The total content (0.9 ml) of the pre-filled syringe should be administered as a subcutaneous injection.
Celotno vsebino (0,9 ml) napolnjene injekcijske brizge je treba dati kot subkutano injekcijo.
The total daily dose at any time during treatment should not exceed 400 mg for any patient.
Skupni dnevni odmerek med zdravljenjem ne sme preseči 400 mg.
The total daily dose in children and adolescents must not exceed 800 mg with CML and 600 mg with Ph+ALL.
Celotni dnevni odmerek pri otrocih in mladostnikih ne sme preseči 800 mg pri KML in 600 mg pri
The total daily dose in children and adolescents must not exceed 800 mg with CML.
Celotni dnevni odmerek pri otrocih in mladostnikih s KML ne sme preseči 800 mg.
The total daily dose in children and adolescents must not exceed 800 mg with CML.
Celotni dnevni odmerek pri otrocih in mladostnikih s KMLne sme preseči 800 mg.
The total daily dose may be divided in two or three doses according to patient’s convenience.
Skupni dnevni odmerek je treba razdeliti v dva ali tri odmerke, kakor je primerno za bolnika.
The total daily dose must not exceed 20 mg/m2 and the total dose per treatment cycle must not exceed 100 mg/m2.
Celoten dnevni odmerek ne sme preseči 20 mg/m2, celotni odmerek v enem krogu zdravljenja pa ne sme preseči 100 mg/m2.
The total daily dose should be divided across the meals of the day.
Skupni dnevni odmerek je treba razdeliti med glavne obroke.
The total daily dose should be divided into equal amounts and given with each meal or feeding (e.g.
Celokupni dnevni odmerek naj se razdeli na enake dele in se daje z vsakim obrokom ali hranjenjem (npr.
The total daily dose usually does not exceed 1 mg.
Skupni dnevni odmerek ponavadi ne presega 1 mg.
The total dose given during a full course of atosiban therapy should preferably not exceed 330.75 mg of atosiban.
Skupni odmerek atosibana med celotnim ciklusom zdravljenja z atosibanom naj ne bi presegel 330,75 mg.
The total dose of Myocet should also take into account any previous, or concomitant, therapy with other cardiotoxic compounds, including anthracyclines and anthraquinones.
Pri skupnem odmerku zdravilaMyocet je treba upoštevati tudi preteklo ali sočasno zdravljenje z drugimi kardiotoksičnimi učinkovinami, vključno z antraciklini in antrakinoni.
The total dose of Nivolumab BMS required can be infused directly as a 10 mg/mL solution or can be diluted to as low as 1 mg/mL with sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection.
Celotni potrebni odmerek zdravila Nivolumab BMS se lahko infundira neposredno v obliki raztopine s koncentracijo 10 mg/ml ali pa se ga predhodno razredči do najnižje koncentracije 1 mg/ml z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje ali s 5-odstotno (50 mg/ml) raztopino glukoze za injiciranje.
The total dose of OPDIVO required can be infused directly as a 10 mg/mL solution or can be diluted to as low as 1 mg/mL with sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection.
Celotni potrebni odmerek zdravila OPDIVO se lahko infundira neposredno v obliki raztopine s koncentracijo 10 mg/ml ali pa se ga predhodno razredči do najnižje koncentracije 1 mg/ml z 0,9-odstotno (9 mg/ml) raztopino natrijevega klorida za injiciranje ali s 5-odstotno (50 mg/ml) raztopino glukoze za injiciranje.
The total dose of perflutren should not exceed 1.6 ml.
Celotni odmerek perflutrena ne sme preseči 1,6 ml.
The total dose on the day of surgery ranged from 50.8 to 126.6 IU/kg.
Razpon skupnega odmerka na dan kirurškega posega je bil od 50,8 do 126,6 i.e./kg.
The total dose, according to the body surface area (BSA) can be calculated as follows: Total dose (mg) = Dose (mg/m2) x BSA (m2)
Celotni odmerek glede na površino telesa (BSA - body surface area) se izračuna tako: Celotni odmerek (mg) = odmerek (mg/m2) x BSA (m2)
The total duration of the study is expected to be 38 months.
Pričakovano celokupno trajanje študije je 38 mesecev.
The total duration of the treatment should be no more than 48 hours.
Zdravljenje v celoti ne sme trajati dlje kot 48 ur.
The total elotuzumab dose in mg = the patient’s weight in kg x 10.
Celotni odmerek elotuzumaba v mg = telesna masa bolnika v kg x 10.
The total etravirine exposure after intake of etravirine 200 mg b.i.d. as part of an antiretroviral regimen was generally higher during pregnancy compared with postpartum (see Table 9).
Po prejemu 200 mg etravirina b.i.d. kot dela protiretrovirusnega zdravljenja je bila celokupna izpostavljenost etravirinu na splošno večja med nosečnostjo kot po porodu (glejte preglednico 9).
The total excreted amount of thiotepa and its identified metabolites accounts for 54-100% of the total alkylating activity, indicating the presence of other alkylating metabolites.
Skupna izločena količina tiotepe in njenih ugotovljenih metabolitov predstavlja 54–100 % vse alkilirajoče aktivnosti, kar kaže na prisotnost še drugih alkilirajočih metabolitov.
The total excreted amount of thiotepa and its identified metabolites accounts for 54-100% of the total alkylating activity, indicating the presence of other alkylating metabolites.
Skupna izločena količina tiotepe in njenih ugotovljenih metabolitov predstavljajo 54–100 % vse alkilirajoče aktivnosti, kar kaže na prisotnost še drugih alkilirajočih metabolitov.
The total exposure of CYP3A4 substrates may increase up to 2-fold on Days 1 and 2 after co- administration with a single 150 mg fosaprepitant dose.
Po sočasni uporabi enkratnega 150 mg odmerka fosaprepitanta in substratov za CYP3A4 se lahko 1. in 2. dan celokupna izpostavljenost substratom za CYP3A4 poveča do 2-krat.
The total exposure up to 24 h post-dose is 124 mg*h/l in children and adolescents and 135 mg*h/l in adult patients.
Popolna izpostavljenost do 24 h po odmerku znaša 124 mg*h/l pri otrocih in mladostnikih ter 135 mg*h/l pri odraslih bolnikih.
The total in-use stability from reconstitution to administration should not exceed 36 hours (24 hours at 2-8°C plus 12 hours room temperature).
Celotni čas od priprave do dajanja zdravila zaradi stabilnosti ne sme preseči 36 ur (24 ur na temperaturi od 2 do 8 °C in 12 ur na sobni temperaturi).
The total injection volume for each treatment session should be up to a maximum of 4 mL.
Celotna količina za injiciranje za vsak terapevtski obisk sme biti do največ 4 ml.